Our observations in clinical samples suggest that miR-582 is downregulated in BCP-ALL, therefore these findings provide a new molecular mechanism of BCP-ALL progression, and suggest that low miR-582 may provide progression advantages in human BCP-ALL, which may insensitive to anti-CD276 therapy. Here, CD276 is linked to acute lymphoblastic leukemia.